| Vitamin A, B, C, D, E, thymosin alpha-1, thymopentin |
Antioxidants/enhance immunity |
|
Oral |
| Selenium, zinc and pyrithione combination |
Enhance immunity |
|
Oral |
| Interferon-β |
Inhibit the replication of SARS-CoV and MERS-CoV replication |
|
Sub-cutaneous |
| Interferon-α |
Inhibit the replication of SARS-CoV and MERS-CoV replication |
5 million U twice a day for a maximum of 10 days |
Inhalation |
| Chloroquine |
Spike (S)-protein angiotensin-converting enzyme 2 (ACE-2) blockers |
500 mg twice daily for a maximum of 10 days |
Oral |
| Mefloquine |
Unknown |
N/A |
Oral |
| Favipiravir |
RNA-dependent RNA polymerase (RdRp) inhibitor |
Proposed dose, 600 mg tid with 1,600 mg first loading dosage for a maximum of 14 days |
Oral |
| Remdesivir |
RdRp inhibitor |
200 mg on day 1 followed by 100 mg daily for 9 days |
Intravenous |
| Darunavir |
Protease inhibitor |
800 mg daily |
Oral |
| Lopinavir/ritonavir |
Protease inhibitor |
200 mg/50 mg, two capsules twice a day for a maximum of 10 days |
Oral |
| Ribavirin |
Nucleoside analogue |
500 mg, 2 to 3 times per day |
Intravenous infusion in combination with lopinavir/ritonavir + interferon-α |
| Arbidol |
|
200 mg three times a day for a maximum of 10 days |
Oral |
| Type II transmembrane serine protease (TMSPSS2) inhibitors (Brand - Camostat) |
TMSPSS2 inhibitors |
|
Oral |
